HC Wainwright Reduces Earnings Estimates for Ekso Bionics

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Ekso Bionics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.11) per share for the quarter, down from their prior forecast of ($0.06). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS and FY2028 earnings at $0.27 EPS.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The firm had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%.

EKSO has been the topic of a number of other reports. StockNews.com initiated coverage on Ekso Bionics in a report on Monday. They issued a “hold” rating on the stock. Lake Street Capital cut their target price on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday.

Ekso Bionics Trading Down 8.0 %

Shares of Ekso Bionics stock opened at $0.44 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The company has a fifty day moving average of $0.61 and a 200 day moving average of $0.82. The company has a market capitalization of $9.64 million, a P/E ratio of -0.67 and a beta of 1.46. Ekso Bionics has a fifty-two week low of $0.37 and a fifty-two week high of $1.64.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.